contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


swedencare-ab-publ-sets-the-additional-purchase-price-for-the-acquisition-of-animal-pharmaceuticals-at-the-maximum-amount-of-approximately-87-million-sek-10musd

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Swedencare has in accordance with the agreement regarding the acquisition of the operations of Animal Pharmaceuticals, which was announced on September 24th 2020, paid an additional purchase...

<div class="mfn-preamble"><p><strong>Swedencare has in accordance with the agreement regarding the acquisition of the operations of Animal Pharmaceuticals, which was announced on September 24th 2020, paid an additional purchase price of approximately 87 million SEK.</strong></p></div><div class="mfn-body"><p>The additional purchase consideration is based on the established EBITDA result of 2.7MUSD during the period July 2019 - June 2020 in the acquired business. The total purchase price for the business amounted to approximately 218 million SEK. The additional purchase price is financed partly from own funds and through a bank loan of 65 million SEK.</p></div><div class="mfn-footer mfn-contacts"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><hr/><p>Håkan Lagerberg, CEO Swedencare<br/>Phone: +46 (0)73 517 01 70<br/>Email: <a href="mailto:hakan.lagerberg@swedencare.se" target="_blank" rel="nofollow noopener">hakan.lagerberg@swedencare.se</a><br/><br/>Jenny Graflind, CFO Swedencare<br/>Phone: +46 (0)73 944 85 54<br/>Email: <a target="_blank" href="mailto:jenny.graflind@swedencare.se" rel="nofollow noopener">jenny.graflind@swedencare.se</a></p><p>FNCA is the Certified Adviser of the Company<br/>Phone: +46 (0) 8 528 00 399<br/>Email: <a href="mailto:info@fnca.se" target="_blank" rel="nofollow noopener">info@fnca.se</a></p><p>Please visit the Company homepage <a target="_blank" href="http://www.swedencare.se/" rel="nofollow noopener">www.swedencare.se</a></p></div><div class="mfn-footer mfn-about"><p><strong class="mfn-heading-1">About Swedencare</strong></p><hr/><p>Swedencare develop, produce, market, and sell premium products on the global and fast-growing market within animal healthcare for cats, dogs and horses. The product groups ProDen PlaqueOff®, Stratford and NutriScience are represented on approximately fifty markets in all parts of the world through ten subsidiaries in the Nordics, United States, France, Spain, Greece, Great Britain and Ireland and with an external distribution network. Swedencare’s sales have increased significantly over the last few years with strong margins and results. The board of directors and the management have a wide and extensive experience of international marketing and sales. </p></div><div class="mfn-footer mfn-attachment mfn-attachment-pdf"><p><strong class="mfn-heading-1">Attachments</strong></p><hr/><p><a target="_blank" class="mfn-generated mfn-primary" href="https://storage.mfn.se/a9ba0969-01a0-46b1-b05e-b9c270e27667/swedencare-ab-publ-sets-the-additional-purchase-price-for-the-acquisition-of-animal-pharmaceuticals-at-the-maximum-amount-of-approximately-87-million-sek-10musd.pdf" rel="nofollow noopener">Swedencare AB (publ) sets the additional purchase price for the acquisition of Animal Pharmaceuticals at the maximum amount of approximately 87 million SEK (10MUSD)</a></p></div>

Swedencare AB (publ) sets the additional purchase price for the acquisition of Animal Pharmaceuticals at the maximum amount of approximately 87 million SEK (10MUSD)

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation